CoQ10 and Cognition a Review and Study Protocol for a 90-Day Randomized Controlled Trial Investigating the Cognitive Effects of Ubiquinol in the Healthy Elderly.

Stough, Con; Nankivell, Madeleine; Camfield, David A; Perry, Naomi L; Pipingas, Andrew; Macpherson, Helen; Wesnes, Keith; Ou, Ruchong; Hare, David L; de Haan, Judy; Head, Geoffrey; Lansjoen, Peter; Langsjoen, Alena; Tan, Brendan; Pase, Matthew P; King, Rebecca; Rowsell, Renee; Zwalf, Oliver; Rathner, Yossi; Cooke, Matthew; Rosenfeldt, Franklin

doi:10.3389/fnagi.2019.00103

Title

CoQ10 and Cognition a Review and Study Protocol for a 90-Day Randomized Controlled Trial Investigating the Cognitive Effects of Ubiquinol in the Healthy Elderly.

Publication Date

2019-05-29

Author(s)

Stough, Con

Nankivell, Madeleine

Camfield, David A

Perry, Naomi L

Pipingas, Andrew

Macpherson, Helen

Wesnes, Keith

Ou, Ruchong

Hare, David L

de Haan, Judy

Head, Geoffrey

Lansjoen, Peter

Langsjoen, Alena

Tan, Brendan

Pase, Matthew P

King, Rebecca

Rowsell, Renee

Zwalf, Oliver

Rathner, Yossi

Cooke, Matthew

Rosenfeldt, Franklin

Subject

Coenzyme Q10

RCT

Ubiquinol

aging

cardiovascular function

cognition

cognitive decline

dementia

Type of document

Journal Article

OrcId

#PLACEHOLDER_PARENT_METADATA_VALUE#

DOI

10.3389/fnagi.2019.00103

Abstract

Introduction: With an aging population there is an important need for the development of effective treatments for the amelioration of cognitive decline. Multiple mechanisms underlie age-related cognitive decline including cerebrovascular disease, oxidative stress, reduced antioxidant capacity and mitochondrial dysfunction. CoQ10 is a novel treatment which has the potential to improve brain function in healthy elderly populations due to established beneficial effects on mitochondrial function, vascular function and oxidative stress. Methods and Analysis: We describe the protocol for a 90-day randomized controlled trial which examines the efficacy of Ubiquinol (200 mg/day) vs. placebo for the amelioration of cognitive decline in a healthy (non-demented) elderly sample, aged 60 years and over. The primary outcome is the effect of Ubiquinol at 90 days compared to baseline on CogTrack composite measures of cognition. Additional cognitive measures, as well as measures of cardiovascular function, oxidative stress, liver function and mood will also be monitored across 30-, 60- and 90- day time points. Data analyses will involve repeated measures analysis of variance (ANOVA). Discussion: This study will be the first of its kind to provide important clinical and mechanistic data regarding the efficacy of Ubiquinol as a treatment for age-related cognitive decline in the healthy elderly with important implications for productivity and quality of life within this age group. Clinical Trial Registration: The trial has been registered with the Australian and New Zealand Clinical Trials Registry (ANZCTRN12618001841268).

Link

link

Citation

Frontiers in Aging Neuroscience 2019; 11: 103

Jornal Title

Frontiers in Aging Neuroscience

ISSN

1663-4365

Austin Health

Files: